Many companies are concerned about the high upfront-costs only to have people discontinue the drugs, negating the long-term benefits, said Ben Barner, clinical pharmacy leader at insurance brokerage Brown & Brown
Tirzepatide is the first dual agonist which has been approved for chronic weight management, but numerous other dual and/or triple agonists (cagrisema, retatrutide, mazdutide and survodutide) are also in phase 3 trials as potential treatments for obesity and its metabolic complications
In a 48-week clinical trial, higher doses consistently led to greater average weight loss: Weight loss by dose (48-week clinical trial) In this trial, at the highest dose (12 mg), people lost an average 24% of their starting weight on average
Januar 2024, abgerufen am 15
Understanding why these changes occur, what to expect, and when symptoms require medical attention helps patients manage treatment effectively whilst maintaining therapeutic benefits
